Lupin stated on Tuesday that it has obtained the international rights from Collegium Pharmaceutical for nasal spray AllerNaze. 
The US is the first market where Lupin will introduce the product.
Reportedly, Lupin expects to increase its US sales strength as it introduces AllerNaze, building on its existence in pediatrics and growing into other fields like allergy.
The USFDA has already sanctioned AllerNaze Nasal spray in curing sneezing, nasal itching and nasal jamming in patients with allergic rhinitis.
Lupin shares traded at Rs.820, which is low with 0.74% in late post noon trade on the Sensex.